Contemporary management of type 2 diabetes: Blood glucose-lowering therapies and glycaemic targets

Medical Journal of Australia

Volumn 189, Issue 5, 2008, Pages 246-248

  Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; EDITORIAL; EUROPE; FLUID RETENTION; FRACTURE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; UNITED STATES;

ALGORITHMS; DECISION TREES; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; REPRODUCIBILITY OF RESULTS;

EID: 53349121549     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb02014.x     Document Type: Editorial

References (17)

1. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721.
2. Ferrannini E. Response to comment on: Nathan DM, Buse JB, Davidson MB et al (2006). Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49: 1711-1721. Diabetologia 2007; 50: 1356-1357.
3. Stratton IM, Adler Al, Neil HA, et al. Association of glycaernia with macrovascular and microvascular complications of type 2, diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
4. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006; 29 Suppi 1: S4-S42.
5. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburicle monotherapy. N Engl J Med 2006; 355: 2427-2443.
6. Takeda Pharmaceuticals North America Inc. Observation of an increased incidence of fractures in female patients who received long-term treatment with Actos (pioglitazone HOI) tablets for type 2 diabetes mellitus. http://www.fda. gov/medwaTCH/safety/2007/Actosma r0807.pdf (accessed May 2007).
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N En9l J Med 2007; 356: 2457-2471.
8. Dahabreh IJ. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008; 5: 116-120.
9. Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008; May 26 [Epub ahead of print].
10. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazoliclinediones. Diabetologia 2008; 51: 8-11.
11. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
12. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
13. American Diabetes Association. Intense blood glucose control yields no significant effect on CVD reduction in VA Diabetes Trial [press release). Alexandria, Va: ADA, 2008; 8 Jun. http://wvvw.diabetes.org/ for-media/pr-intense-blood-glucose-control-yields-no-significant- effect-on-cvd-reduc-tion.jsp (accessed Jun 2008).
14. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
15. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357: 28-38.
16. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
17. American Diabetes Association. Statement from the American Diabetes Association related to the ACCORD trial announcement [press release]. Alexandria, Va: ADA, 2008; 6 Feb. http://www.diabetes.org/for-media/ pr-ada-statement-related-to-accord-trail-announcement-020608.jsp (accessed May 2008).